Revolution Medicines, INC Form 4 insider transactions

Revolution Medicines General Counsel, Jeff Cislini, executed a pre-planned sale of 12,000 common shares following the exercise of stock options.

Revolution Medicines CEO Mark A. Goldsmith exercised stock options and subsequently sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, Inc., executed a pre-planned sale of 25,000 common shares after exercising stock options.

Revolution Medicines General Counsel Jeff Cislini sold 1,799 shares of common stock for $44.26 per share pursuant to a pre-arranged 10b5-1 trading plan.

Revolution Medicines' Chief Medical Officer, Wei Lin, sold 2,160 shares of common stock to cover tax obligations from restricted stock unit vesting.

Revolution Medicines' President of R&D, Stephen Michael Kelsey, sold 5,367 shares of common stock to cover tax withholding obligations from RSU vesting.

Revolution Medicines, Inc. CEO Mark A. Goldsmith reported a pre-scheduled future sale of 13,411 shares of common stock for September 16, 2025, to cover tax obligations from RSU vesting.

Revolution Medicines' Chief Operating Officer, Margaret Horn, sold 4,775 shares of common stock to cover tax obligations from RSU vesting.

Revolution Medicines General Counsel Jeff Cislini filed a Form 4 detailing a future sale of 1,869 common shares on September 16, 2025, to cover tax obligations from RSU vesting.

Revolution Medicines' CFO, Jack Anders, sold 2,320 shares of common stock on September 16, 2025, at $45.8249 per share to cover tax withholding from RSU vesting.

Revolution Medicines' President of R&D, Stephen Michael Kelsey, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Revolution Medicines' Chief Financial Officer, Jack Anders, executed pre-planned transactions involving the exercise of stock options and subsequent sale of common stock.

Revolution Medicines, Inc. CEO Mark A. Goldsmith reported the exercise of 37,000 stock options, increasing his direct beneficial ownership in the company.

Revolution Medicines, Inc. Director Sandra Horning acquired 3,142 shares of common stock and 11,574 stock options on June 26, 2025, increasing her beneficial ownership in the company.

Revolution Medicines, Inc. Director Sushil Patel reported the acquisition of 3,142 shares of common stock and 11,574 stock options as part of an equity grant on June 26, 2025.

Revolution Medicines, Inc. Director Lorence H. Kim reported the acquisition of 3,142 shares of common stock and 11,574 stock options as part of an equity grant.

Revolution Medicines, Inc. Director and 10% Owner Alexis Borisy reported the acquisition of 3,142 Restricted Stock Units and 11,574 stock options, increasing his beneficial ownership in the company.

Revolution Medicines, Inc. Director Flavia Borellini reported the acquisition of 3,142 restricted stock units and 11,574 stock options on June 26, 2025, as part of her compensation.

Revolution Medicines, Inc. Director Elizabeth M. Anderson acquired 3,142 Restricted Stock Units and 11,574 stock options on June 26, 2025, increasing her beneficial ownership in the company.

Revolution Medicines, Inc. Director Frank Clyburn reported the acquisition of 2,806 shares of common stock and 10,337 stock options on June 26, 2025, increasing his beneficial ownership in the company.

Jeff Cislini, General Counsel of Revolution Medicines, Inc., sold 1,912 shares of common stock for approximately $75,760 under a pre-arranged 10b5-1 trading plan.

Revolution Medicines, Inc.'s Chief Operating Officer, Margaret A. Horn, sold 3,510 shares of common stock on June 16, 2025, at a weighted average price of $39.83, to cover tax withholding obligations related to RSU vesting.

Revolution Medicines, Inc. CEO Mark A. Goldsmith sold 13,496 shares of common stock for $39.83 per share on June 16, 2025, to cover tax withholding obligations related to restricted stock unit vesting.

Revolution Medicines, Inc.'s General Counsel, Jeff Cislini, sold 1,878 shares of common stock for approximately $39.83 per share to cover tax withholding obligations related to RSU vesting, as disclosed in a recent SEC Form 4 filing.

Revolution Medicines, Inc. Chief Financial Officer, Jack Anders, sold 2,170 shares of common stock on June 16, 2025, at a weighted average price of $39.83 per share, primarily to satisfy tax withholding obligations related to restricted stock unit vesting.

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, Inc., sold 4,289 shares of common stock to cover tax withholding obligations related to RSU vesting.

Revolution Medicines' Chief Medical Officer, Wei Lin, sold 2,173 shares of common stock on June 16, 2025, at a weighted average price of $39.83 per share, as part of a pre-arranged Rule 10b5-1 plan to cover tax withholding from RSU vesting.

Frank Clyburn, a director at Revolution Medicines, files an amendment to a previous Form 4 to correct the amount of a stock option award granted on August 5, 2024.

Jeff Cislini, General Counsel of Revolution Medicines, sold 2,041 shares of common stock on March 20, 2025, under a pre-arranged 10b5-1 trading plan.

Jeff Cislini, General Counsel of Revolution Medicines, sold 1,458 shares of common stock on March 17, 2025, to cover tax obligations related to vesting restricted stock units.